Pharmstandard Plasma

History

2022: Establishing a Company

On November 10, 2022, Pharmstandard registered a new company in Moscow, which was named Pharmstandard Plasma. Its main activity is the production of medicines, namely blood products.

Vladimir Chupikov, who is also a member of the collegial executive body of Pharmstandard, has been appointed General Director of Pharmstandard Plasma LLC. By mid-November 2022, the new company does not yet have licenses. There are no blood preparations in the portfolio of Pharmstandard itself, but earlier other companies in the group had them.

Pharmstandard has created a company for the production of blood products Pharmstandard Plasma

We are talking about three recombinant factors of blood coagulation: eptacog alpha, moroktokog alpha, nonakog alpha. The first was developed by Pharmstandard and Lecco (later included in the Pharmstandard group) in 2009. Then the companies announced the creation of a joint venture "Generium," at the facilities of which they were going to produce eptakog alpha. In 2013-2014, Generium registered two other blood factors.

Another project for the production of blood products is associated with Rostec. It all started in 2001 with a project for the construction of a blood preparation plant of the Federal State Budgetary Institution Rosplazma. The first two lines were built in 2009, but they were never put into operation, as the customer wanted to expand production. However, construction stopped, as the customer and the general contractor began to sort things out in the courts. Construction was mothballed.

In May 2022, Bashinform reported that a subsidiary of Pharmstandard - UfaVita plans to complete the construction of a workshop for the production of the blood coagulation factor VIII drug in the third quarter, and to produce it in 2023. According to the GRLS, the company in 2020 began a clinical trial of Plasmaate (INN coagulation factor VIII), we are talking about the first phase, which should end in July 2023^[1]

Notes